Newamsterdam Pharma Stock Current Valuation
| NAMS Stock | 20.84 0.21 1.00% |
Valuation analysis of NewAmsterdam Pharma helps investors to measure NewAmsterdam Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 514.4 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (2.63). Fundamental drivers impacting NewAmsterdam Pharma's valuation include:
Price Book 5.1331 | Enterprise Value 1.5 B | Enterprise Value Ebitda 27.6291 | Price Sales 57.889 | Enterprise Value Revenue 45.3206 |
Undervalued
Today
Please note that NewAmsterdam Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of NewAmsterdam Pharma is based on 3 months time horizon. Increasing NewAmsterdam Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NewAmsterdam stock is determined by what a typical buyer is willing to pay for full or partial control of NewAmsterdam Pharma. Since NewAmsterdam Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NewAmsterdam Stock. However, NewAmsterdam Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.84 | Real 22.86 | Target 25.16 | Hype 21.16 |
The intrinsic value of NewAmsterdam Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NewAmsterdam Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NewAmsterdam Pharma helps investors to forecast how NewAmsterdam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NewAmsterdam Pharma more accurately as focusing exclusively on NewAmsterdam Pharma's fundamentals will not take into account other important factors: NewAmsterdam Pharma Company Current Valuation Analysis
NewAmsterdam Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NewAmsterdam Pharma Current Valuation | 1.52 B |
Most of NewAmsterdam Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewAmsterdam Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NewAmsterdam Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Current Valuation. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NewAmsterdam Pharma has a Current Valuation of 1.52 B. This is 89.4% lower than that of the Biotechnology sector and 67.23% lower than that of the Health Care industry. The current valuation for all United States stocks is 90.84% higher than that of the company.
NewAmsterdam Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in current valuation category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.52 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 84.04 % | ||||
| Number Of Shares Shorted | 718.04 K | ||||
| Price To Book | 5.13 X | ||||
| Price To Sales | 57.89 X | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (165.69 M) | ||||
| Net Income | (160.27 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Short Ratio | 2.92 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Target Price | 37.0 | ||||
| Number Of Employees | 62 | ||||
| Beta | -0.001 | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
| Net Asset | 347.1 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.